Administration of continuous/intermittent olaparib in ovarian cancer patients with a germline BRCA1/2 mutation to determine an optimal dosing schedule for the tablet formulation

J. Mateo; M. Friedlander; C. Sessa; K. Leunen; S. Nicum; C. Gourley; A. Fielding; K. Bowen; S. Kaye; L. R. Molife

Administration of continuous/intermittent olaparib in ovarian cancer patients with a germline BRCA1/2 mutation to determine an optimal dosing schedule for the tablet formulation

J. Mateo, M. Friedlander, C. Sessa, K. Leunen, S. Nicum, C. Gourley, A. Fielding, K. Bowen, S. Kaye, L. R. Molife

Research output: Contribution to journal › Meeting abstract › peer-review

Original language	English
Pages (from-to)	S161-S161
Number of pages	1
Journal	European Journal of Cancer
Volume	49
Publication status	Published - Sep 2013
Event	17th ECCO / 38th ESMO / 32nd ESTRO European Cancer Congress on Reinforcing Multidisciplinarity - Amsterdam, Netherlands Duration: 27 Sep 2013 → 1 Oct 2013

Cite this

@article{7320f669a5e74b01a6961d23d83f23a7,

title = "Administration of continuous/intermittent olaparib in ovarian cancer patients with a germline BRCA1/2 mutation to determine an optimal dosing schedule for the tablet formulation",

author = "J. Mateo and M. Friedlander and C. Sessa and K. Leunen and S. Nicum and C. Gourley and A. Fielding and K. Bowen and S. Kaye and Molife, {L. R.}",

year = "2013",

month = sep,

language = "English",

volume = "49",

pages = "S161--S161",

journal = "European Journal of Cancer",

issn = "0959-8049",

publisher = "PERGAMON-ELSEVIER SCIENCE LTD",

note = "17th ECCO / 38th ESMO / 32nd ESTRO European Cancer Congress on Reinforcing Multidisciplinarity ; Conference date: 27-09-2013 Through 01-10-2013",

}

TY - JOUR

T1 - Administration of continuous/intermittent olaparib in ovarian cancer patients with a germline BRCA1/2 mutation to determine an optimal dosing schedule for the tablet formulation

AU - Mateo, J.

AU - Friedlander, M.

AU - Sessa, C.

AU - Leunen, K.

AU - Nicum, S.

AU - Gourley, C.

AU - Fielding, A.

AU - Bowen, K.

AU - Kaye, S.

AU - Molife, L. R.

PY - 2013/9

Y1 - 2013/9

M3 - Meeting abstract

VL - 49

SP - S161-S161

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

T2 - 17th ECCO / 38th ESMO / 32nd ESTRO European Cancer Congress on Reinforcing Multidisciplinarity

Y2 - 27 September 2013 through 1 October 2013

ER -